[1] YANG H, XU D, SCHMID R A, et al. Biomarker-guided targeted and immunotherapies in malignant pleural mesothelioma[J]. Therapeutic Advances In Medical Oncology, 2020(12): 1758835920971421. [2] OEHL K, VRUGT B, OPITZ I, et al. Heterogeneity in malignant pleural mesothelioma[J]. Journal of Molecular Sciences, 2018,19(6): 1603. [3] LIU X, QIAN K, LU G, et al. Identification of genes and pathways involved in malignant pleural mesothelioma using bioinformatics methods[J]. BMC Medical Genomics, 2021,14(1): 104. [4] ZHOU J, ZHONG H, ZHANG J, et al. Development and validation of a prognostic signature for malignant pleural mesothelioma[J]. Frontiers in Oncology, 2019,9:78. [5] Clough E, Barrett T.The gene expression omnibus database[J]. Methods in Molecular Biology, 2016,1418: 93-110. [6] Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks[J]. Genome Research, 2003,13(11): 2498-2504. [7] Suraokar M B, Nunez M I, Diao L, et al. Expression profiling stratifies mesothelioma tumors and signifies deregulation of spindle checkpoint pathway and microtubule network with therapeutic implications[J]. Annals of Oncology, 2014,25(6): 1184-1192. [8] Huang D W, Sherman B T, Lempicki R A.Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources[J]. Nature Protocols, 2009,4(1): 44-57. [9] Gene Ontology Consortium: going forward[J]. Nucleic Acids Research, 2015,43(Database issue): D1049-D1056. [10] Kanehisa M, Furumichi M, Tanabe M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs[J]. Nucleic Acids Research, 2017,45(D1): D353-D361. [11] Doncheva N T, Morris J H, Gorodkin J, et al. Cytoscape stringapp: network analysis and visualization of proteomics data[J]. Journal of Proteome Research, 2019,18(2): 623-632. [12] LIU J, ZHOU S, LI S, et al. Eleven genes associated with progression and prognosis of endometrial cancer (EC) identified by comprehensive bioinformatics analysis[J]. Cancer Cell International, 2019,19: 136. [13] ZHENG X, LIU X, ZHENG H, et al. Integrated bioinformatics analysis identified COL11A1 as an immune infiltrates correlated prognosticator in pancreatic adenocarcinoma[J]. International Immunopharmacology, 2021,90: 106982. [14] Vazquez-Villa F, Garcia-Ocana M, Galvan J A, et al. COL11A1/(pro)collagen 11A1 expression is a remarkable biomarker of human invasive carcinoma-associated stromal cells and carcinoma progression[J]. Tumor Biology, 2015,36(4): 2213-2222. [15] ZENG B, ZHOU M, WU H, et al. SPP1 promotes ovarian cancer progression via integrin beta1/FAK/AKT signaling pathway[J]. Oncotargets and Therapy, 2018,11: 1333-1343. [16] LI L, LEI Q, ZHANG S, et al. Screening and identification of key biomarkers in hepatocellular carcinoma: Evidence from bioinformatic analysis[J]. Oncology Reports, 2017,38(5): 2607-2618. [17] ZHANG L, SUN L, ZHANG B, et al. Identification of differentially expressed genes (DEGs) relevant to prognosis of ovarian cancer by use of integrated bioinformatics analysis and validation by immunohistochemistry assay[J]. Medical Science Monitor, 2019,25: 9902-9912. [18] Zalenski A A, Majumder S, De K, et al. An interphase pool of KIF11 localizes at the basal bodies of primary cilia and a reduction in KIF11 expression alters cilia dynamics[J]. Scientific Reports, 2020,10(1): 13946. [19] Kato T, Lee D, Wu L, et al. Kinesin family members KIF11 and KIF23 as potential therapeutic targets in malignant pleural mesothelioma[J]. International Journal of Oncology, 2016,49(2): 448-456. [20] Morani F, Bisceglia L, Rosini G, et al. Identification of overexpressed genes in malignant pleural mesothelioma[J]. International Journal of Molecular Sciences, 2021,22(5):2738. [21] Rasmussen A H, Rasmussen H B, Silahtaroglu A.The DLGAP family: neuronal expression, function and role in brain disorders[J]. Molecular Brain, 2017,10(1): 43. [22] ZHENG R, SHI Z, LI W, et al. Identification and prognostic value of DLGAP5 in endometrial cancer[J]. Peer Journal, 2020,8: e10433. [23] MO M L, CHEN Z, LI J, et al. Use of serum circulating CCNB2 in cancer surveillance[J]. The International Journal Of Biological Markers, 2010,25(4): 236-242. [24] HUANG H, YANG Y, ZHANG W, et al. TTK regulates proliferation and apoptosis of gastric cancer cells through the Akt-mTOR pathway[J]. FEBS Open Biology, 2020,10(8): 1542-1549. [25] XIAO C, GONG J, JIE Y, et al. NCAPG Is a promising therapeutic target across different tumor types[J]. Frontiers In Pharmacology, 2020,11: 387. [26] WU Y, LIN Y, PAN J, et al. NCAPG promotes the progression of lung adenocarcinoma via the TGF-beta signaling pathway[J]. Cancer Cell International, 2021,21(1): 443. [27] FU J, ZHANG X, YAN L, et al. Identification of the hub gene BUB1B in hepatocellular carcinoma via bioinformatic analysis and in vitro experiments[J]. Peer Journal, 2021,9: e10943. [28] BAI Y, WANG X, HOU J, et al. Identification of a five-gene signature for predicting survival in malignant pleural mesothelioma patients[J]. Frontiers In Genetics, 2020,11:899. |